Sustainability is more than just a buzzword these days: it’s a core part of companies’ mission statements and workplace culture. As the climate change crisis continues to worsen, local, state, and federal governments have started offering incentives for companies to incorporate sustainability into their buildings and practices. And many companies have been doing so.
That’s the assessment of Rich Bendis, President and Chief Executive Officer of BHI, who has championed the region’s transition into a top four biopharma hub in the United States. However, given the state of the economy and the amount of money being invested, Bendis said it is unrealistic to expect the region to move up the ranking of the top 10 life sciences regions compiled by Genetic Engineering & Biotechnology News (GEN).
The first gene therapy to be approved by the FDA occurred in late 2017. It was Spark Therapeutics’ Luxturna, approved for a rare, genetic form of blindness. Since then, a handful of additional gene therapies have been approved, including bluebird bio’s Zynteglo for beta-thalassemia, which is expected to launch in March 2023. The Alliance for Regenerative Medicine predicts five more gene therapies may be approved this year.
Serving as a professor at Johns Hopkins for over a decade, Dr. Le recently decided to step out of her comfort zone and start her own company in Baltimore’s Inner Harbor, Gigantest, which provides next-level metabolomics services for scientists and physicians at leading institutions around the world.
Curing HIV is an expensive endeavor, and under Sabrina Campbell’s watchful eye, an innovative service is funding the gene therapy trial that may lead to the end of the HIV epidemic. At the beginning of the COVID-19 pandemic, there was a shortage of PCR testing, which prompted American Gene Technologies® to open its own laboratory to bridge supply and demand. Every dollar of profit from the COVID-19 PCR tests performed in the clinical laboratory pays for the HIV Cure Program’s Phase 1 human trial. With such a critical responsibility, the clinical laboratory must operate uninterrupted, which is why we’re thrilled to highlight Sabrina Campbell, the lab manager who’s aiding a potential HIV cure with COVID-19 testing revenue.
A stay interview is an interview conducted with current employees to assess their job satisfaction as well as why employees are “staying” with your company. During a stay interview, you may ask your employees several questions with the goal of learning both what makes your company a good place to work as well as what may need improvement to increase employee retention.
In a wide-ranging discussion, the panel discussed how they got into working with mRNA, what they’ve seen as key drivers in the field (COVID-19, of course, was major), and what they’re excited to see in the future.
Numerous biopharma companies and organizations presented at the JP Morgan Healthcare conference held this week in San Francisco. Three with either headquarters in Philadelphia or ties to the area, were of note for their overview of 2022 and their outlook for 2023 and beyond. Here’s a look at presentations by Amicus Therapeutics, Avantor, and Jazz Pharmaceuticals.
This year, 2023, Century is focused on the execution of its vision by advancing multiple development candidates, primarily the Phase I ELiPSE-1 clinical trial of CNTY-101 in patients with relapsed or refractory CD19+ B-cell malignancies.
In the hustle and bustle of planning experiments, growing a business and improving services, visual branding often stumbles toward the bottom of the priorities list for life science companies. While companies used to be able to get away with quickly putting a logo together and creating a scrappy website using a pre-existing Wix template, an increasingly crowded life sciences market is making leadership teams rethink their visual presence.